Advances in Assessment of Bioequivalence

  • Solubility based on highest dose strength of an IR product
  • Requirements for acquiring BCS based waiver for in-vivo BA/BE studies
  • Establishment of bioequivalence criteria
  • Drugs possessing narrow therapeutic index
  • Volume of distribution
  • Waivers of In Vivo Study Requirements
  • Biopharmaceutics Classification System (BCS)

Related Conference of Advances in Assessment of Bioequivalence

Advances in Assessment of Bioequivalence Conference Speakers